Target Price | DKK938.20 |
Price | DKK420.50 |
Potential |
123.12%
register free of charge
|
Number of Estimates | 15 |
15 Analysts have issued a price target Zealand Pharma 2026 .
The average Zealand Pharma target price is DKK938.20.
This is
123.12%
register free of charge
DKK1,150.00
173.48%
register free of charge
DKK730.00
73.60%
register free of charge
|
|
A rating was issued by 16 analysts: 14 Analysts recommend Zealand Pharma to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Zealand Pharma stock has an average upside potential 2026 of
123.12%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million DKK | 62.69 | 5,060.08 |
81.71% | 7,971.59% | |
EBITDA Margin | -1,983.12% | 57.24% |
1,175.58% | 102.89% | |
Net Margin | -1,830.21% | 75.25% |
613.83% | 104.11% |
15 Analysts have issued a sales forecast Zealand Pharma 2025 . The average Zealand Pharma sales estimate is
This results in the following potential growth metrics:
13 Analysts have issued an Zealand Pharma EBITDA forecast 2025. The average Zealand Pharma EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Zealand Pharma Analysts have issued a net profit forecast 2025. The average Zealand Pharma net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share DKK | -16.24 | 53.90 |
30.55% | 431.90% | |
P/E | 7.80 | |
EV/Sales | 4.33 |
10 Analysts have issued a Zealand Pharma forecast for earnings per share. The average Zealand Pharma EPS is
This results in the following potential growth metrics and future valuations:
Analyst | Rating | Action | Date |
---|---|---|---|
BERENBERG |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
CANTOR FITZGERALD |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
KBC SECURITIES |
Locked
➜
Locked
|
Locked | Mar 24 2025 |
BTIG |
Locked
➜
Locked
|
Locked | Mar 17 2025 |
DNB MARKETS |
Locked
➜
Locked
|
Locked | Mar 13 2025 |
JEFFERIES |
Locked
➜
Locked
|
Locked | Mar 11 2025 |
WILLIAM BLAIR & COMPANY |
Locked
➜
Locked
|
Locked | Mar 11 2025 |
Analyst Rating | Date |
---|---|
Locked
BERENBERG:
Locked
➜
Locked
|
Mar 31 2025 |
Locked
CANTOR FITZGERALD:
Locked
➜
Locked
|
Mar 31 2025 |
Locked
KBC SECURITIES:
Locked
➜
Locked
|
Mar 24 2025 |
Locked
BTIG:
Locked
➜
Locked
|
Mar 17 2025 |
Locked
DNB MARKETS:
Locked
➜
Locked
|
Mar 13 2025 |
Locked
JEFFERIES:
Locked
➜
Locked
|
Mar 11 2025 |
Locked
WILLIAM BLAIR & COMPANY:
Locked
➜
Locked
|
Mar 11 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.